Cargando…
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-t...
Autores principales: | Vida Navas, Elena María, Martínez Lorca, Alberto, Sancho Gutiérrez, Aintzane, Sanz Gómez, Lucia, Navarro Martínez, Teresa, Grande Pulido, Enrique, Carrato Mena, Alfredo, Gajate Borau, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082310/ https://www.ncbi.nlm.nih.gov/pubmed/33935979 http://dx.doi.org/10.3389/fendo.2021.676973 |
Ejemplares similares
-
Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023) -
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017) -
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021) -
Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
por: Abou Jokh Casas, Estephany, et al.
Publicado: (2020) -
The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)